Ledger.

Company

BLUE KNIGHT

Coverage

Stories naming BLUE KNIGHT. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.

Also Brandon Capital portfolio

Something wrong? Tell us